---
document_datetime: 2025-10-30 12:44:21
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/m-m-rvaxpro-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: m-m-rvaxpro-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 5.0059131
conversion_datetime: 2025-12-27 15:30:57.961092
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## M-M-RvaxPro

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproduct lifecycleprocedures,you mayneedtoalsorefertoEPAR-Proceduralsteps taken andscientific informationafterauthorisation(archive).

| Applicationnumber   | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision IssuedÂ²/ amendedon   | Product Information affected3   | Summary   |
|---------------------|----------------------------------------|-------------------------------------|------------------------------------------|---------------------------------|-----------|
| Article 61(3) /     | Notification acc.Article61(3)-Accepted | 30/10/2025                          |                                          | PL                              |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/N/0000308492                      | Update of the package leaflet with revised contactdetailsoflocalrepresentatives.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |            |     |             |                                                                                                                                                                                                                                            |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IA / EMA/VR/0000293349 | B.I.d.1.a Re-test period/storage period - B.I.d.1.a.1 Reduction - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 30/09/2025 | N/A |             |                                                                                                                                                                                                                                            |
| Variation type II / EMA/VR/0000253336 | This was an applicationfor avariation following a worksharing procedure according toArticle20ofCommissionRegulation(EC) No 1234/2008. C.IHUMANANDVETERINARYMEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilancedata-Accepted Updateofsection4.8oftheSmPCinorder to add\"skin granuloma(associated with vaccine derived rubella virus)\"to thelist of adverse drug reactions with the frequency \"notknown\"based on clinical trial data and post-marketing reports; the Package Leaflet isupdated accordingly.In addition,the MAH took the opportunity to implement various minor updates to the Product Information text of M-M-RvaxPro and ProQuad.In addition, the list of local representatives in the PL is being revised. | 24/07/2025 |     | SmPC and PL | SmPCsection 4.8is updated to add\"skin granuloma (associated with vaccine derived rubella virus)\"to thelist of adverse drug reactions with the frequency\"not known\".For more information, pleaserefertotheSummaryofProduct Characteristics. |

<div style=\"page-break-after: always\"></div>

| Variation type II / EMA/VR/0000263499   | B.II.d.1 Change in the specification parameters and/or limits of the finished product - B.1II.d.1.e Change outside the approved specifications limits range - Accepted   | 12/06/2025   | N/A   |
|-----------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|